{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T19:46:44Z","timestamp":1792525604737,"version":"4.5.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"DOI":"10.1186\/s12931-026-03801-4","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T01:18:52Z","timestamp":1783473532000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Depemokimab: toward biannual biologic therapy for severe eosinophilic asthma"],"prefix":"10.1186","volume":"27","author":[{"given":"Kostas A.","family":"Papavassiliou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vassiliki A.","family":"Gogou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5803-4527","authenticated-orcid":false,"given":"Athanasios G.","family":"Papavassiliou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"key":"3801_CR1","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1007\/s40265-026-02310-4","volume":"86","author":"M Cazzola","year":"2026","unstructured":"Cazzola M, Matera MG, Ora J, Calzetta L, Rogliani P. Current and emerging biologic therapies for severe asthma. Drugs. 2026;86:813\u201340. https:\/\/doi.org\/10.1007\/s40265-026-02310-4.","journal-title":"Drugs"},{"key":"3801_CR2","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1016\/j.medj.2024.10.022","volume":"5","author":"S Nolasco","year":"2024","unstructured":"Nolasco S, Crimi C. Depemokimab, the first ultra-long-acting anti-IL-5 monoclonal antibody for severe eosinophilic asthma. Med. 2024;5:1452\u20135. https:\/\/doi.org\/10.1016\/j.medj.2024.10.022.","journal-title":"Med"},{"key":"3801_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2025.e44247","volume":"12","author":"M Orecchia","year":"2026","unstructured":"Orecchia M, et al. Generation and preclinical assessment of depemokimab, an enhanced IL-5 antagonist monoclonal antibody. Heliyon. 2026;12:e44247. https:\/\/doi.org\/10.1016\/j.heliyon.2025.e44247.","journal-title":"Heliyon"},{"key":"3801_CR4","doi-asserted-by":"publisher","unstructured":"Jackson DJ, Wechsler ME, Brusselle G, Buhl R. Targeting the IL-5 pathway in eosinophilic asthma: A comparison of anti-IL-5 versus anti-IL-5 receptor agents. Allergy. 2024;79:2943\u201352. https:\/\/doi.org\/10.1111\/all.16346. Erratum in: Allergy. 2025;80:1557. https:\/\/doi.org\/10.1111\/all.16541.","DOI":"10.1111\/all.16346."},{"key":"3801_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1817893","volume":"17","author":"W Ou","year":"2026","unstructured":"Ou W, et al. Role of IL-5 in eosinophil-associated diseases and prospects for multi-target therapy. Front Immunol. 2026;17:1817893. https:\/\/doi.org\/10.3389\/fimmu.2026.1817893.","journal-title":"Front Immunol"},{"key":"3801_CR6","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1056\/NEJMoa2406673","volume":"391","author":"DJ Jackson","year":"2024","unstructured":"Jackson DJ, et al. Twice-yearly depemokimab in severe asthma with an eosinophilic phenotype. N Engl J Med. 2024;391:2337\u201349. https:\/\/doi.org\/10.1056\/NEJMoa2406673.","journal-title":"N Engl J Med"},{"key":"3801_CR7","doi-asserted-by":"publisher","unstructured":"Wechsler ME, et al. Early and Sustained Efficacy of Depemokimab in Type 2 Asthma: A Pooled Analysis of the SWIFT-1\/-2 Studies.\u00a0J Allergy Clin Immunol Pract. 2026 Mar 27:S2213\u20132198(26)00209\u20136. https:\/\/doi.org\/10.1016\/j.jaip.2026.03.008. Epub ahead of print.","DOI":"10.1016\/j.jaip.2026.03.008"},{"key":"3801_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s12865-025-00777-6","volume":"27","author":"BA Gill","year":"2025","unstructured":"Gill BA, et al. Efficacy and safety of depemokimab in asthma with eosinophilic phenotype: a systematic review and meta-analysis of randomized controlled trials. BMC Immunol. 2025;27:2. https:\/\/doi.org\/10.1186\/s12865-025-00777-6.","journal-title":"BMC Immunol"},{"key":"3801_CR9","doi-asserted-by":"publisher","first-page":"1766647","DOI":"10.3389\/falgy.2026.1766647","volume":"7","author":"E Heffler","year":"2026","unstructured":"Heffler E, et al. Depemokimab demonstrates efficacy in patients with type 2 asthma with comorbid CRSwNP: Phase III SWIFT-1\/-2 analysis. Front Allergy. 2026;7:1766647. https:\/\/doi.org\/10.3389\/falgy.2026.1766647.","journal-title":"Front Allergy"},{"key":"3801_CR10","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1093\/ajrccm\/aamag031","volume":"212","author":"G Chupp","year":"2026","unstructured":"Chupp G, et al. Switching to twice-yearly depemokimab from mepolizumab\/benralizumab in severe asthma: a multicenter, randomized, double-blind, phase 3A clinical trial (NIMBLE). Am J Respir Crit Care Med. 2026;212:921\u201335. https:\/\/doi.org\/10.1093\/ajrccm\/aamag031.","journal-title":"Am J Respir Crit Care Med"},{"key":"3801_CR11","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1007\/s12325-025-03457-4","volume":"43","author":"DJ Jackson","year":"2026","unstructured":"Jackson DJ, et al. Safety and tolerability of twice-yearly depemokimab in patients with asthma and chronic rhinosinusitis with nasal polyps: pooled results from SWIFT-1\/-2 and ANCHOR-1\/-2. Adv Ther. 2026;43:880\u201397. https:\/\/doi.org\/10.1007\/s12325-025-03457-4.","journal-title":"Adv Ther"},{"key":"3801_CR12","doi-asserted-by":"publisher","unstructured":"McDowell, et al. Analysis of airway inflammation demonstrates a mechanism for T2-biologic failure in asthma. J Allergy Clin Immunol. 2025;156:911\u201322. https:\/\/doi.org\/10.1016\/j.jaci.2025.05.031.","DOI":"10.1016\/j.jaci.2025.05.031"},{"key":"3801_CR13","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.jaci.2025.03.025","volume":"156","author":"I Agache","year":"2025","unstructured":"Agache I, et al. Personalized therapeutic approaches for asthma. J Allergy Clin Immunol. 2025;156:503\u201322. https:\/\/doi.org\/10.1016\/j.jaci.2025.03.025.","journal-title":"J Allergy Clin Immunol"},{"key":"3801_CR14","doi-asserted-by":"publisher","first-page":"2400207","DOI":"10.1183\/13993003.00207-2024","volume":"64","author":"N Zounemat Kermani","year":"2024","unstructured":"Zounemat Kermani N, et al. Radiomultiomics: quantitative CT clusters of severe asthma associated with multiomics. Eur Respir J. 2024;64:2400207. https:\/\/doi.org\/10.1183\/13993003.00207-2024.","journal-title":"Eur Respir J"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-026-03801-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-026-03801-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-026-03801-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T01:18:52Z","timestamp":1783473532000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12931-026-03801-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3801"],"URL":"https:\/\/doi.org\/10.1186\/s12931-026-03801-4","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,8]]},"assertion":[{"value":"6 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"276"}}